Catalent, Inc. (CTLT)
NYSE: CTLT · Real-Time Price · USD
59.79
+0.79 (1.34%)
Nov 21, 2024, 12:19 PM EST - Market open
Catalent Revenue
Catalent had revenue of $1.02B in the quarter ending September 30, 2024, with 4.18% growth. This brings the company's revenue in the last twelve months to $4.42B, up 4.71% year-over-year. In the fiscal year ending June 30, 2024, Catalent had annual revenue of $4.38B with 2.77% growth.
Revenue (ttm)
$4.42B
Revenue Growth
+4.71%
P/S Ratio
2.42
Revenue / Employee
$248,427
Employees
17,800
Market Cap
10.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 4.38B | 118.00M | 2.77% |
| Jun 30, 2023 | 4.26B | -539.00M | -11.22% |
| Jun 30, 2022 | 4.80B | 804.00M | 20.11% |
| Jun 30, 2021 | 4.00B | 904.00M | 29.22% |
| Jun 30, 2020 | 3.09B | 576.00M | 22.88% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Smith & Nephew | 5.64B |
| Encompass Health | 5.22B |
| AptarGroup | 3.57B |
| Exact Sciences | 2.69B |
| Globus Medical | 2.48B |
| Exelixis | 2.08B |
| Medpace Holdings | 2.07B |
| Sarepta Therapeutics | 1.64B |
CTLT News
- 7 days ago - EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal - Reuters
- 16 days ago - Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings - Reuters
- 16 days ago - Catalent, Inc. Reports First Quarter Fiscal 2025 Results - Business Wire
- 17 days ago - EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6 - Reuters
- 4 weeks ago - Roche comes out against clearing takeover of drug manufacturer Catalent - Reuters
- 4 weeks ago - Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout - Reuters
- 4 weeks ago - Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings - Business Wire
- 4 weeks ago - Consumer groups ask FTC to block Novo Holdings-Catalent deal - Reuters